On October 7, 2026, Pulse Biosciences, Inc. announced that it has achieved its enrollment target of 164 evaluable patients in its NANOPULSE-AF clinical study. This study evaluates the company’s nPulse™ Cardiac Catheter System for the treatment of atrial fibrillation, a condition affecting millions globally. This milestone is significant as it demonstrates the company’s commitment to advancing medical technology and improving patient outcomes in the surgical and medical instruments sector.
Pulse Biosciences, Inc., trading under the ticker PLSE on the Nasdaq, specializes in surgical and medical instruments and apparatus. The company has been active in the market, with recent filings including multiple 8-K reports and a 10-Q, reflecting its ongoing developments and financial performance. The company is classified under the SIC code 3841, which pertains to surgical and medical instruments and apparatus.
The filing states, "On October 7, 2026, Pulse Biosciences, Inc. announced that it had achieved its enrollment target of 164 evaluable patients in its NANOPULSE-AF clinical study evaluating the Company’s nPulse™ Cardiac Catheter System for the treatment of atrial fibrillation." This study is a pivotal clinical investigation designed to assess the safety and effectiveness of the nPulse system in patients with drug-resistant, symptomatic, paroxysmal atrial fibrillation.
This achievement may have a significant impact on various stakeholders, including healthcare providers, patients suffering from atrial fibrillation, and investors interested in the medical technology sector. The successful enrollment across 15 clinical sites indicates strong interest and support from the medical community, which could lead to increased adoption of the nPulse system if the study results are favorable.
The filing does not specify what happens next, but the company is expected to provide updates as patients complete follow-up assessments. The primary safety and effectiveness endpoints of the study will be evaluated at 6 and 12 months post-ablation, which will be crucial in determining the future of the nPulse system in clinical practice.